Enanta Historical Balance Sheet

ENTA Stock

USD 12.91 0.37 2.95%

Trend analysis of Enanta Pharmaceuticals balance sheet accounts such as Other Current Liabilities of 42.4 M or Total Current Liabilities of 75.8 M provides information on Enanta Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Enanta Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Enanta Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Enanta Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Enanta Pharmaceuticals is a good buy for the upcoming year.

Enanta Pharmaceuticals Inventory

(31.85 Million)

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.

About Enanta Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Enanta Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Enanta Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Enanta Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Enanta currently owns. An asset can also be divided into two categories, current and non-current.

Enanta Pharmaceuticals Balance Sheet Chart

At present, Enanta Pharmaceuticals' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 75.8 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 18 M.

Common Stock Shares Outstanding Total Assets Other Current Liab Total Current Liabilities

Add Fundamental

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of Enanta Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Enanta Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Enanta Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Enanta Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Enanta Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Enanta Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.At present, Enanta Pharmaceuticals' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 75.8 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 18 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	20.9M	35.1M	40.3M	42.4M
Total Assets	375.4M	462.3M	531.6M	327.6M

Other Current Liab Total Assets

Enanta Pharmaceuticals balance sheet Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets	Common Stock
Common Stock Shares Outstanding		0.79	0.48	0.47	0.63	-0.44	0.51	-0.6	0.21	0.53	0.62	0.6	0.17	0.43	0.73	0.61	0.84	0.73	0.21	0.43	0.85	0.28	0.44	-0.73	0.75	0.84
Total Assets	0.79		0.67	0.65	0.85	-0.41	0.63	-0.8	0.26	0.8	0.8	0.59	0.33	0.38	0.97	0.81	0.78	0.97	0.16	0.55	0.92	0.28	0.54	-0.67	0.98	0.78
Other Current Liab	0.48	0.67		0.99	0.34	-0.71	0.95	-0.53	-0.47	0.51	0.85	0.26	0.85	0.05	0.69	0.58	0.48	0.66	0.74	0.39	0.72	0.83	0.93	-0.36	0.69	0.49
Total Current Liabilities	0.47	0.65	0.99		0.31	-0.71	0.95	-0.55	-0.5	0.46	0.87	0.25	0.84	0.07	0.67	0.5	0.47	0.64	0.77	0.35	0.7	0.85	0.93	-0.35	0.66	0.49
Total Stockholder Equity	0.63	0.85	0.34	0.31		-0.15	0.31	-0.72	0.62	0.81	0.58	0.72	0.0	0.46	0.76	0.71	0.72	0.78	-0.29	0.56	0.7	-0.16	0.2	-0.74	0.79	0.72
Other Liab	-0.44	-0.41	-0.71	-0.71	-0.15		-0.76	0.21	0.5	-0.34	-0.53	-0.28	-0.66	0.35	-0.39	-0.26	-0.46	-0.36	-0.54	-0.51	-0.63	-0.6	-0.76	0.36	-0.39	-0.47
Property Plant And Equipment Net	0.51	0.63	0.95	0.95	0.31	-0.76		-0.44	-0.51	0.39	0.81	0.17	0.91	0.09	0.67	0.48	0.5	0.66	0.73	0.23	0.73	0.82	0.99	-0.38	0.67	0.52
Net Debt	-0.6	-0.8	-0.53	-0.55	-0.72	0.21	-0.44		-0.29	-0.6	-0.88	-0.46	-0.16	-0.31	-0.79	-0.55	-0.55	-0.74	-0.16	-0.43	-0.64	-0.26	-0.35	0.51	-0.79	-0.56
Retained Earnings	0.21	0.26	-0.47	-0.5	0.62	0.5	-0.51	-0.29		0.39	-0.13	0.46	-0.72	0.38	0.17	0.26	0.17	0.2	-0.78	0.24	0.01	-0.75	-0.6	-0.25	0.19	0.15
Accounts Payable	0.53	0.8	0.51	0.46	0.81	-0.34	0.39	-0.6	0.39		0.56	0.73	0.16	0.15	0.68	0.82	0.53	0.67	-0.08	0.82	0.68	0.04	0.3	-0.47	0.73	0.53
Cash	0.62	0.8	0.85	0.87	0.58	-0.53	0.81	-0.88	-0.13	0.56		0.35	0.59	0.2	0.83	0.57	0.59	0.78	0.52	0.39	0.76	0.63	0.74	-0.49	0.82	0.6
Non Current Assets Total	0.6	0.59	0.26	0.25	0.72	-0.28	0.17	-0.46	0.46	0.73	0.35		-0.08	0.37	0.4	0.5	0.59	0.4	-0.24	0.69	0.57	-0.14	0.09	-0.6	0.44	0.58
Non Currrent Assets Other	0.17	0.33	0.85	0.84	0.0	-0.66	0.91	-0.16	-0.72	0.16	0.59	-0.08		-0.02	0.39	0.3	0.18	0.37	0.75	0.01	0.48	0.8	0.95	-0.07	0.39	0.2
Other Assets	0.43	0.38	0.05	0.07	0.46	0.35	0.09	-0.31	0.38	0.15	0.2	0.37	-0.02		0.35	0.29	0.34	0.38	-0.13	-0.26	0.29	-0.09	0.05	-0.38	0.34	0.34
Cash And Short Term Investments	0.73	0.97	0.69	0.67	0.76	-0.39	0.67	-0.79	0.17	0.68	0.83	0.4	0.39	0.35		0.72	0.73	0.99	0.26	0.42	0.88	0.36	0.58	-0.61	0.99	0.74
Net Receivables	0.61	0.81	0.58	0.5	0.71	-0.26	0.48	-0.55	0.26	0.82	0.57	0.5	0.3	0.29	0.72		0.55	0.73	0.09	0.53	0.72	0.19	0.42	-0.45	0.79	0.55
Common Stock Total Equity	0.84	0.78	0.48	0.47	0.72	-0.46	0.5	-0.55	0.17	0.53	0.59	0.59	0.18	0.34	0.73	0.55		0.74	0.04	0.42	0.86	0.14	0.44	-0.96	0.74	1.0
Short Term Investments	0.73	0.97	0.66	0.64	0.78	-0.36	0.66	-0.74	0.2	0.67	0.78	0.4	0.37	0.38	0.99	0.73	0.74		0.23	0.4	0.87	0.33	0.57	-0.63	0.99	0.74
Non Current Liabilities Total	0.21	0.16	0.74	0.77	-0.29	-0.54	0.73	-0.16	-0.78	-0.08	0.52	-0.24	0.75	-0.13	0.26	0.09	0.04	0.23		-0.06	0.25	0.99	0.77	0.11	0.23	0.06
Other Current Assets	0.43	0.55	0.39	0.35	0.56	-0.51	0.23	-0.43	0.24	0.82	0.39	0.69	0.01	-0.26	0.42	0.53	0.42	0.4	-0.06		0.53	0.04	0.16	-0.37	0.47	0.42
Other Stockholder Equity	0.85	0.92	0.72	0.7	0.7	-0.63	0.73	-0.64	0.01	0.68	0.76	0.57	0.48	0.29	0.88	0.72	0.86	0.87	0.25	0.53		0.37	0.67	-0.74	0.89	0.87
Total Liab	0.28	0.28	0.83	0.85	-0.16	-0.6	0.82	-0.26	-0.75	0.04	0.63	-0.14	0.8	-0.09	0.36	0.19	0.14	0.33	0.99	0.04	0.37		0.84	0.01	0.35	0.16
Property Plant And Equipment Gross	0.44	0.54	0.93	0.93	0.2	-0.76	0.99	-0.35	-0.6	0.3	0.74	0.09	0.95	0.05	0.58	0.42	0.44	0.57	0.77	0.16	0.67	0.84		-0.32	0.58	0.46
Preferred Stock Total Equity	-0.73	-0.67	-0.36	-0.35	-0.74	0.36	-0.38	0.51	-0.25	-0.47	-0.49	-0.6	-0.07	-0.38	-0.61	-0.45	-0.96	-0.63	0.11	-0.37	-0.74	0.01	-0.32		-0.62	-0.96
Total Current Assets	0.75	0.98	0.69	0.66	0.79	-0.39	0.67	-0.79	0.19	0.73	0.82	0.44	0.39	0.34	0.99	0.79	0.74	0.99	0.23	0.47	0.89	0.35	0.58	-0.62		0.74
Common Stock	0.84	0.78	0.49	0.49	0.72	-0.47	0.52	-0.56	0.15	0.53	0.6	0.58	0.2	0.34	0.74	0.55	1.0	0.74	0.06	0.42	0.87	0.16	0.46	-0.96	0.74

Click cells to compare fundamentals

Enanta Pharmaceuticals Account Relationship Matchups

Enanta Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	19.9M	20.2M	20.6M	21.0M	24.1M	18.0M
Total Assets	486.1M	438.8M	375.4M	462.3M	531.6M	327.6M
Other Current Liab	14.2M	22.4M	20.9M	35.1M	40.3M	42.4M
Total Current Liabilities	24.2M	36.2M	29.8M	62.8M	72.2M	75.8M
Total Stockholder Equity	455.6M	399.4M	321.3M	216.7M	249.2M	273.1M
Other Liab	2.9M	1.1M	558K	454K	408.6K	388.2K
Property Plant And Equipment Net	15.6M	10.7M	29.7M	34.7M	39.9M	41.9M
Net Debt	(79.0M)	(51.9M)	(18.7M)	(58.9M)	(53.0M)	(55.6M)
Retained Earnings	127.6M	48.6M	(73.2M)	(207.0M)	(238.0M)	(226.1M)
Accounts Payable	5.7M	9.5M	6M	4.1M	4.7M	4.3M
Cash	87.1M	57.2M	44.0M	85.4M	98.2M	103.1M
Non Current Assets Total	49.3M	119.8M	63.7M	39.5M	45.4M	56.9M
Other Assets	12.0M	1.0M	700K	4.7M	5.4M	5.6M
Cash And Short Term Investments	386.6M	244.0M	249.2M	369.9M	425.4M	231.2M
Net Receivables	23.5M	60.8M	49.0M	39.6M	45.6M	28.8M
Common Stock Total Equity	197K	201K	202K	208K	239.2K	183.8K
Short Term Investments	299.5M	186.8M	205.2M	284.5M	327.2M	184.7M
Liabilities And Stockholders Equity	486.1M	438.8M	375.4M	462.3M	531.6M	327.6M
Non Current Liabilities Total	6.4M	3.2M	24.2M	182.8M	210.2M	220.7M
Other Current Assets	26.7M	51.4M	13.4M	13.3M	15.3M	13.8M
Other Stockholder Equity	325.5M	349.5M	396.6M	423.3M	486.8M	263.7M
Total Liab	30.6M	39.4M	54.1M	245.5M	282.4M	296.5M
Property Plant And Equipment Gross	15.6M	10.7M	51.6M	58.5M	67.2M	70.6M
Total Current Assets	436.8M	319.0M	311.7M	422.8M	486.2M	270.6M
Accumulated Other Comprehensive Income	844K	(382K)	(3.7M)	(1.2M)	(1.1M)	(1.0M)
Common Stock	201K	202K	208K	211K	242.7K	187.5K
Property Plant Equipment	10.9M	8.6M	10.7M	29.7M	34.2M	35.9M
Short Long Term Debt Total	8.1M	5.3M	25.3M	26.5M	30.5M	32.0M
Net Tangible Assets	462.5M	455.6M	399.4M	321.3M	369.5M	365.3M
Capital Surpluse	298.4M	327.0M	351.0M	398.0M	457.7M	317.9M
Long Term Investments	16.4M	65.0M	32.6M	108.4M	29.3M	0.0
Non Current Liabilities Other	6.4M	558K	454K	160.1M	184.1M	193.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CART	Maplebear Common Stock
OPK	Opko Health
AVAI	Avant Technologies

Additional Information and Resources on Investing in Enanta Stock

When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:

How To Invest In Enanta

Details

Is Enanta Stock a good investment?

Details

What is Enanta Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.

You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.66)

Earnings Share

(6.25)

Revenue Per Share

3.455

Quarterly Revenue Growth

(0.04)

Return On Assets

(0.23)

The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Enanta Historical Balance Sheet

Enanta Pharmaceuticals Inventory

(31.85 Million)

About Enanta Balance Sheet Analysis

Enanta Pharmaceuticals Balance Sheet Chart

Common Stock Shares Outstanding

Total Assets

Total Current Liabilities

Enanta Pharmaceuticals balance sheet Correlations

Enanta Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Enanta Pharmaceuticals balance sheet Accounts

Also Currently Popular

Additional Information and Resources on Investing in Enanta Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Total Current Liabilities	+ 0.99	Other Current Liab
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Short Term Investments	+ 0.99	Cash And Short Term Investments
Total Current Assets	+ 0.99	Cash And Short Term Investments
Total Current Assets	+ 0.99	Short Term Investments

Common Stock	- 0.96	Preferred Stock Total Equity
Preferred Stock Total Equity	- 0.96	Common Stock Total Equity
Cash	- 0.88	Net Debt
Net Debt	- 0.8	Total Assets
Total Current Assets	- 0.79	Net Debt
Cash And Short Term Investments	- 0.79	Net Debt